Inhibition of Fibrinolysis by Coagulation Factor XIII.

The inhibitory effect of coagulation factor XIII (FXIII) on fibrinolysis has been studied for at least 50 years. Our insight into the underlying mechanisms has improved considerably, aided in particular by the discovery that activated FXIII cross-links 2-antiplasmin (2AP) to fibrin. In this review, the most important effects of different cross-linking reactions on fibrinolysis are summarized. A distinction is made between fibrin-fibrin cross-links studied in purified systems and fibrin-2AP cross-links studied in plasma or whole blood systems. While the formation of chain dimers in fibrin does not affect clot lysis, the formation of chain polymers has a weak inhibitory effect. Only strong cross-linking of fibrin, associated with high molecular weight chain polymers and/or chain multimers, results in a moderate inhibition fibrinolysis. The formation of fibrin-2AP cross-links has only a weak effect on clot lysis, but this effect becomes strong when clot retraction occurs. Under these conditions, FXIII prevents 2AP being expelled from the clot and makes the clot relatively resistant to degradation by plasmin.